The present disclosure provides methods and kits for treating and classifying individuals at risk of or suffering from a neurological and/or mitochondrial dysfunction or disorder. In general, the individuals are treated and/or classified based on the presence of a change-of-function mutation in nuclear DNA that encodes TNF receptor-associated protein 1 (TRAP1). Treatment involves the administration of a therapeutically effective amount of an antioxidant.
